Introduction: Despite demonstrable risk of venous thromboembolism (VTE), thromboprophylaxis continues to be underutilized in hospitalized cancer patients. Our study evaluated institutional VTE prophylaxis rates after devising a series of strategic interventions to longitudinally improve adherence rates over a period of eight years. Methods and materials: Between 2004 and 2012, a series of interventions were implemented to improve the thromboprophylaxis rate among patients with solid tumours hospitalized at our institution using quality improvement methodology. Interventions included development of guidelines and institutional policies coupled with educational in-services for physicians, nurses and pharmacists and engagement of the Cancer Quality Committee. Thromboprophylaxis rates were monitored to assess response to interventions. Results: At the outset in 2004, 11 of 57 (19.3%) eligible patients received appropriate pharmacological prophylaxis and formed the baseline of our analysis. Post-2009 policy implementation and educational sessions, 46.5% of an eligible 185 inpatients were administered thromboprophylaxis. Following a two-year grace period to allow for policy acceptance, three audits were conducted in 2011 for which an average prophylaxis rate of 62.3% resulted. In 2012, following another round of educational sessions, a 96.7% rate was achieved and maintained ten weeks later. Minimal bleeding risk was observed during this eight year initiative. Conclusion: A reproducible 96.7% prophylaxis uptake rate was the result of our perseverance and persistence in believing that culture change was inevitable through continuously collaborating with stakeholders at all levels.
Introduction
Cancer, in combination with hospitalization and chemotherapy are major risk factors for the development of venous thromboembolism (VTE) [1] [2] [3] [4] [5] [6] [7] [8] . As demonstrated by population-based studies, cancer was associated with a 4.1-fold greater risk of thrombosis, whereas the use of chemotherapy increased the risk 6.5-fold [5, 31] . Accordingly, VTE is ranked as the second leading cause of death in hospitalized cancer patients [3, [9] [10] [11] . The magnitude of this situation creates a need for VTE prophylaxis using anticoagulation in this patient population [9, 12] .
The recognition of VTE as a frequent complication of cancer was responded to by multiple cancer organizations since 2006 [13] [14] [15] [16] . These organizations have been key to the development and implementation of internationally recognized VTE prophylaxis guidelines [17] . Recently, hospital accreditation by Accreditation Canada has emphasized the importance of VTE prophylaxis through its Required Organizational Practice (ROP) measures as a first step toward standardization of this practice [18] .
Adherence to VTE prophylaxis guidelines continues to be a substantial issue since uptake is at physician discretion thus voluntary [14] . Recent publications have reported low compliance rates and underutilization of prophylaxis in hospitalized cancer patients, but the majority of studies published to date evaluated VTE prophylaxis rates at a single time point [9, 12, [20] [21] [22] [23] [24] [25] . The British Columbia Cancer Agency (BCCA) reported longitudinal VTE prophylaxis rates but over a relatively short period of 20 weeks between 2011 and 2012 [26] . Thus, longitudinal studies that measure compliance of VTE prophylaxis uptake rates over time are lacking. This fact, along with the acknowledgement of VTE as a significant cause of morbidity and mortality in hospitalized cancer patients motivated physicians, pharmacists and nurses at Princess Margaret Cancer Centre to design and implement a VTE prophylaxis policy and monitor its uptake rates over a period of eight years. The primary objective of our quality improvement initiative was to achieve a 100% prophylaxis rate over time through a series of interventions and periodic monitoring of performance.
Materials and methods

Literature review
Baseline understanding of the publications and guidelines relevant to venous thromboembolism risk and prophylaxis uptake in cancer patients was done in 2004 and again in 2009 and 2012 through a comprehensive literature search using Medline, EMBASE, Cochrane and Google Scholar. Using the advanced search tool found within each of these databases, the following keywords were used as search terms along with various combinations of the Boolean connectors "AND" and "OR": vte, venous thromboembolism, prophylaxis, cancer and hospitalized. Other additional search criteria placed a restriction to more contemporary articles published from 2009 to May 2012 in order to investigate more recent work being conducted in this area.
Study setting
Princess Margaret Cancer Centre is a tertiary care hospital with 130 inpatient beds [19] . Forty-one of these beds are allocated to the two solid tumour inpatient units. Each solid tumour unit is comprised of a clinical pharmacist, unit clerk, physiotherapists, occupational therapists and a team of nurses. In addition to attending physicians, there are two clinical associates (one radiation, and one medical oncology) who are responsible for the management of all patients admitted to the solid tumour units.
Target population
All solid tumour patients admitted for greater than 48 hours were selected for analysis of VTE prophylaxis rates. Medical and radiation oncology patients were considered eligible for thromboprophylaxis in the absence of any absolute contraindications. These have evolved in tandem with the published guidelines varying over the 8 years. Consequently, direct contraindications vary slightly between 2004, 2009, 2011 and 2012 and will be explained in further detail throughout the following sections. Patients admitted to the solid tumour units were significantly medically unwell because of their previous treatments they received. There were patients who would have had many lines of chemotherapy that they received during ambulatory care. Now on admission, patients presented with chemotherapy-resistant diseases, recurrences and disease progression with metastases. Management of febrile neutropenia, pain and iatrogenically-induced conditions such as cardiotoxicity, diabetes, constipation, bowel obstructions, cord compressions, SVC syndrome and other treatment-related toxicity have been well documented. Supportive care offered to address these issues. Observation and management of serious toxicities necessitating admission from phase I clinical studies. A subset of patients were routinely admitted for the purpose of receiving brachytherapy. Cancer-related venous thromboembolism was also one of the characteristics of the reason for admission to the units.
Data collection
To calculate the VTE prophylaxis rates for each of our 2004, 2009, 2011 and 2012 time periods, a similar basic algorithm was followed each time as summarized in Fig. 1 . We did not discriminate amongst the use of various pharmacological anticoagulants (i.e. low-molecular weight heparin (LMWH), low-dose unfractionated heparin, fondaparinux or Vitamin K antagonists). The specific interventions implemented prior to, and following data collection varied between each year and are described in additional detail in Fig. 2 .
Through statistical comparison, anticoagulation and thromboprophylaxis rates were assessed amongst the various time points and adherence audits. Although mechanical prophylaxis is a viable option for patients with absolute contraindications to receiving pharmacological prophylaxis, its use at Princess Margaret Cancer Centre is limited and hence not evaluated in this study. This is due to the relative cost, and more importantly lack of evidence demonstrating its efficacy in cancer patients since most data is relevant to surgical patients [36] . As a standard of care at our institution with continuous effort to measure quality improvement in thromboprophylaxis, the research ethics board (REB) approval was not required.
Description of interventions
2004
With a vision to evaluate VTE prophylaxis in the in-patient setting, a series of strategic interventions were adapted at our institution ( Fig. 2) : Proposed VTE prophylaxis guidelines were approved by the University Health Network Oncology Subcommittee, Pharmacy & Therapeutics (P&T) Committee, and the Medical Advisory Committee (MAC). Guideline implementation occurred thereafter through formal education sessions provided to physicians, nurses and pharmacists at Princess Margaret Cancer Centre, and distribution of pocket-sized reference cards to clinical staff. Data was collected prospectively following enrollment of patients admitted to the solid tumour units over a 17-week period between January 29 and June 1, 2004. Pharmacists assigned to these two inpatient wards were recruited to assist with this process. VTE prophylaxis data for each patient was collected from the patient's medical chart as well as the hospital's computer system. A list of all patients along with relevant demographic information was obtained from the clinical resource administrator and used to identify patients with high-risk versus low-risk solid tumour types. Patients were considered high-risk and thereby eligible for prophylaxis if they had either a primary or metastatic tumour of the brain, lung, ovary, pancreas, stomach, colon, rectum, liver or kidney. Absolute contraindications at the time of this analysis included: active bleeding, severe thrombocytopenia (platelet count less than 50 × 10 9 /L), history of heparin-induced thrombocytopenia (HIT), hypersensitivity to heparin or LMWH and uncontrolled hypertension (defined as systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 100 mmHg) [27] [28] [29] . Although a longitudinal progression of this work was our mandate, scarcity of supportive literature/guidelines were available to augment this path. Nonetheless, our team remain vigilant throughout the following years, while being attentive to the development of the initial draft of the pre-printed order (PPO) and how best to make it available to the frontline staff. By 2006/7 with the publication of internationally recognized VTE prophylaxis guidelines by ASCO, a renewed energy bolstered our confidence in the design of the following residency project in 2009 in hope to enhance the cause.
2009
By this time, internationally recognized guidelines became available which recommended VTE prophylaxis for all hospitalized cancer patients in the absence of any absolute contraindications. Patients had to be exempt from the following contraindications in order to qualify as eligible for either prophylactic or therapeutic anticoagulation: active bleeding, hypersensitivity to heparin or LMWH, severe thrombocytopenia (defined as a platelet count less than 50 × 10 9 /L), uncontrolled hypertension (defined as systolic blood pressure greater than 200/ 120 mmHg), hemodialysis, and previous history of HIT [16, 27, 29, 35] . As an initial step, revised institutional VTE prophylaxis guidelines and the PPO form by pharmacy were prepared and approved by institutional committees. Due to lack of uptake of the PPO forms, these documents were discontinued six months later. Data collection then occurred between the scheduled dates of February 23 to May 29, 2009 . Patient admission, transfer and discharge reports were reviewed, to ensure all admitted patients were captured. Drug usage reports were generated retrospectively at monthly intervals to help distinguish patients receiving prophylaxis from those receiving treatment.
2010
As part of the 10th annual Princess Margaret Hospital Conference, key leaders in this field were invited to promote awareness of the current practices and armamentarium against VTE, as well as discuss the significance of compliance to VTE prophylaxis in the hospitalized setting.
2011
The establishment of VTE prophylaxis as a ROP by Accreditation Canada beginning January 2011 prompted our institution to take further action in this area. Over the year, nursing staff strongly advocated for the administration of VTE prophylaxis to brachytherapy patients who had previously not received VTE prophylaxis, secondary to a rise in the incidental findings of pulmonary emboli. Accounting for this group of patients in our VTE audits appreciably improved prophylaxis rates since they were previously deemed "eligible but not receiving prophylaxis" during VTE audits. In addition, as a reminder for assessment of VTE prophylaxis, clinical pharmacists on the unit were encouraged to engage in discussion with the physician upon completing medication reconciliation at the time of patient admission. Three randomly-selected, one-day crosssectional audits of thromboprophylaxis rates were conducted on April 6, June 17 and July 20, 2011 by a team of clinical pharmacists to ensure validity and reproducibility of the other one-day audits (Table 1, Fig. 2 ). In 2011, patients were deemed ineligible for VTE prophylaxis if they had any one of the following exclusion criteria: active bleeding; high risk of bleeding (potential gastrointestinal bleed, platelets less than 50 × 10 9 /L and hemoglobin count less than 70g/L); and patient fully mobile with expected length of stay less than 48 hours [21] .
2012
For the year 2012, we adopted the Plan-Do-Study-Act (PDSA) model, as described by the Clinical Practice Improvement Unit of the Northern Sydney Central Coast Health [40] . The PDSA process follows a stepwise approach that is particularly useful to instituting changes that involve multiple persons or systems as opposed to anticipating on having the perfect plan at the outset [40, 41] . A team of multidisciplinary healthcare providers was assembled and an initial audit was undertaken in May 2012 to allow comparison to our 2011 VTE prophylaxis rates. Admitted patients were screened daily for active anticoagulation orders before 11:00 am (Fig. 1) . Given the updated 2012 NCCN guidelines, active bleeding or platelet count less than 50 × 10 9 /L were considered absolute contraindications to VTE prophylaxis [7] . By means of a continuous feedback mechanism, hospital clinicians were made aware of previous rates and data collected from prior audits; relevant frontline healthcare professionals were provided with the most recent literature relevant to VTE prophylaxis, as well as the 12th edition CHEST guidelines; further support arose from presentations made to clinical members of the Cancer Quality Committee; and pharmacists, physicians and nurses were informed that ambulating patients without any absolute contraindications also qualified for VTE prophylaxis. Prior to this clarification there was some uncertainty in this area due to the lack of a formalized definition of "mobility" for hospitalized patients. Thereby better adherence to VTE prophylaxis was encouraged for this group of patients. Furthermore, a VTE prophylaxis tool was added to the medication reconciliation tracking spreadsheet used by pharmacists to ensure that all patients were assessed for VTE prophylaxis in relation to admission. With these tools and reminder systems in place, a second VTE prophylaxis audit was conducted between the scheduled dates of June 18 to June 22, 2012. Following the completion of our June audit, additional randomly-selected, one-day-a-week audits were scheduled for a period of ten-weeks thereafter to ascertain sustainability of our post-June 2012 prophylaxis rate. Over these 10 weeks, medication orders for 164 newly admitted patients were assessed for compliance to VTE prophylaxis. These one-day audits were conducted using a similar procedure as described for the previous 2012 audits. Please refer to Fig. 2 for a summary of all interventions assumed by healthcare providers between 2004 and 2012 to encourage compliance to VTE prophylaxis.
Statistical methods
Categorical variables such as prophylaxis uptake were summarized with counts and percentages. A chi-square test was used to determine Development and implementation of institutional VTE prophylaxis guidelines following approval by the Research Ethics Board Multidisciplinary team education sessions, development of pocket sized reference cards Baseline assessment of VTE prophylaxis uptake rate & symptomatic VTE incidence as a secondary objective over a 17-week period
2004
Alignment of institutional practices with published VTE prophylaxis guidelines Stakeholder buy-in (policy/guidelines through various committees) PPO form implemented but unfortunately phased -out 6 months later due to slow uptake Multidisciplinary team education sessions Measure VTE prophylaxis uptake success 
2012
Frontline staff advocate for VTE prophylaxis for brachytherapy patients Series of 3 randomly-selected, one-day, cross-sectional VTE prophylaxis audits to ensure validity and reproducibility of 2011 rates Ward pharmacists engage in discussion with MD upon completing a medication reconciliation with reminder for VTE prophylaxis assessment
Continue to engage frontline MD, RN and pharmacists with results of 2012 audits. Encourage to self-reflect on previous rates and strategize areas of improvement as part of the PDSA cycle methodology (conduct regular meetings) "Ambulating" patients are to receive appropriate prophylaxis Most recent literature & 12 th ed. of CHEST guidelines presented Assessment tool available to pharmacists in the form of an electronic spreadsheet to assess eligibility upon admission Continuous audits undertaken to reassess prophylaxis rates following strategy implementation Randomly selected once-a-week audits performed to ensure stability of achieved prophylaxis rates uptake All P-values were 2-sided and for the statistical analyses, P b 0.05 was considered to indicate a significantly different result. Data analysis was performed using SAS Version 9.2 (SAS Institute, Inc., Cary, NC). Fig. 3 and broken down into further detail in Table 1 .
Results
Anticoagulation and thromboprophylaxis rates calculated for 2004, 2009, 2011 and 2012 audits are summarized in
2004
Over a 17-week period, 237 patients were admitted to the solid tumour units. Ninety-two of these patients were identified as belonging to the targeted high-risk group and the remaining 145 was classified as the low-risk tumour type. Being a relative contraindication at the time, patients with low-risk tumours were excluded from analysis. In addition, 30 of the 92 high-risk solid tumour patients were not included in the study because of their absolute contraindications to receiving pharmacological prophylaxis. Please refer to Table 1 for a more detailed breakdown of the 19.3% prophylaxis rate determined for this audit year.
2009
Between February 23 and May 29, 2009, 367 patients were admitted, and 150 patients were excluded (130 with length of stay less than 48 hours and 20 patients with absolute contraindications). Please refer to Table 1 for a more detailed breakdown.
2011
Three one-day audits of patients admitted were conducted to determine compliance rates following implementation of the VTE prophylaxis policy in 2009. For each of the three audits, between 37-38 patients were admitted, and 25-27 were considered eligible for VTE prophylaxis after excluding patients with a length of stay less than 48hours, absolute contraindications and those receiving therapeutic anticoagulation. Prophylaxis rates of 56.0%, 66.7% and 64.0% were determined for audits 1 to 3 respectively. An average prophylaxis rate of 62.3% was derived by adding the number of patients for each of the three audits to obtain a total. These totals are further described in Table 1 .
2012
During the first audit occurring in May, 54 patients were admitted to solid tumour units. From this group of patients, 3 were receiving therapeutic anticoagulation while 25 out of an eligible 37 patients were receiving appropriate pharmacological prophylaxis. This resulted in a 67.6% prophylaxis rate, and also closely resembled the rate calculated in 2011. As described earlier, following this audit came about significant tactical modifications to our current VTE prophylaxis adherence strategies. The second 2012 audit occurred in June over a period of five days and resulted in a 96.7% prophylaxis rate. Further details of this audit are described in Table 1 . In addition, randomly-selected, one-day-aweek audits were also performed, and similar, if not higher rates were maintained 10-weeks after the June 2012 audit (Table 2) (Fig. 4) .
Given the study methodologies described earlier, the 2004 and 2009 study years were consistent in the manner of evaluating VTE prophylaxis uptake over an extended timeframe (14-17 weeks 
Discussion
An important point of contrast between 2004 and more recent practice arises from the fact that in 2004, only patients with high-risk solid tumour types were considered eligible for VTE prophylaxis, whereas today we recommend thromboprophylaxis for all hospitalized cancer patients in the absence of direct contraindications. This recommendation is likely due to the lack of guidelines at the time since several studies pertained to identifying VTE risk factors (including cancer), as well as clinical trials comparing the safety and efficacy of various anticoagulants were published after 2004 [27, [30] [31] [32] [33] . Likewise, the guidelines developed by ASCO, NCCN or CHEST were only published in 2007. The FRONTLINE survey also suggests that concerns regarding bleeding risk and misguided impressions of patients' risk for thromboembolic events may explain some hesitance by oncologists in prescribing VTE prophylaxis [37] .
Following the implementation of our 2009 institutional thromboprophylaxis policy, although rates improved, the uptake rates were barely reaching the 50% mark. We speculated that the post-policy implementation phase was still in its infancy and clinicians were in the process of accepting the new policy. This was evident by the lack of uptake of the PPO sheets during the data collection period. Perhaps further reinforcement of the policy and use of the PPO forms could have resulted in improved thromboprophylaxis rates. All three one-day cross sectional audits were carried out using relatively consistent methods and also demonstrated similar anticoagulation rates. These rates represented a progressive incremental improvement in VTE prophylaxis uptake but failed to meet the desired 100% mark likely due to similar reasons described earlier.
The discouraging results of the May 2012 audit in anticipation of significant adherence lead us to regroup and devise a change management strategy. As patient's advocate, all clinicians on the floor 
Table 2
Anticoagulation and prophylaxis rates collected from solid tumour patients during randomly selected, one-day-a-week audits post June 2012 audit achievement.
were encouraged to proactively assess the need for VTE prophylaxis, and ensure that every patient on the floor was accounted for.
Pharmacists and nurses on the units also worked very closely with the radiation and medical oncology services on the ward to optimize patient safety. Regularly scheduled team meetings and PDSA cycles rejuvenated and strengthened the processes toward fulfilling the primary objective. These strategies proved to be very effective as demonstrated by our 96.7% prophylaxis rate calculated for the second audit.
Limitations
One of the major limitations to our analysis would be the lack of congruency amongst the study designs. The 2004 and 2009 studies were completed as residency projects while the 2011 and 2012 analyses were completed as short-term audits due to limited allocation of resources and personnel for study follow-up. This resulted in inconsistencies between sample sizes and the duration of data collection for each of these studies, and compelled us to make the assumptions described earlier when conducting the Cochran-Armitage trend analyses.
In retrospect, considering that it took almost eight years to develop a solid change management strategy and set a benchmark VTE prophylaxis rate is quite extensive. However, perhaps this length of time was essential to achieve a sustainable 96.7% prophylaxis rate due to the evolving literature, revision of prophylaxis guidelines and changing groups to offer prophylaxis to. This is made true to the realm of culture change and that as things evolve with time, the results become more apparent.
Conclusions & future recommendations
Our record showed that we have been able to achieve, and maintain a VTE prophylaxis rate of 96.7% for 10 weeks in solid tumour units at Princess Margaret Cancer Centre. Ithas been both challenging and rewarding. We believe through our persistent efforts, VTE prophylaxis should be well-embedded within our practice as demonstrated here. What is significant, however, is the infrastructure necessary to maintain the momentum and results. In order to continue to validate our results, a number of operational approaches are needed. Additional randomly selected, unannounced monthly audits are underway to ensure consistency of optimal prophylaxis rates over the long-term. Developing and administering a survey to all hospital oncologists to assess their understanding of VTE and reasons for abstaining from ordering prophylaxis may further allow us to gain a better grasp of future prospects.
The use of technology and our Electronic Patient Records (EPR) system in the hospital is another tool that can be used more optimally to achieve our 100% uptake goal. Clinicians access this program on a routine basis in order to review patient history, medications and order laboratory or imagining tests. Instituting electronic alerts in EPR that identify patients at risk of developing a VTE and also reminds physicians to order appropriate prophylaxis has been proven to improve compliance in this area [25, 38, 39] . Previous studies have demonstrated that computer alerts improved compliance and also reduced the risk of VTE by as much as 41% [25, 38, 39] . To elaborate, perhaps adopting a system utilizing forced functions for prescribers to consider VTE prophylaxis for newly admitted patients may assist with streamlining the process. In this case, a valid reason for not ordering VTE prophylaxis must be selected otherwise the program will not be able to proceed any further. The reasons for abstention can be reviewed in a timely manner to address areas of improvement. This suggestion will greatly assist us in upholding the standard described within our institutional guidelines.
Another possible strategy to maintain VTE prophylaxis compliance rates among our cancer inpatients would be to educate the patients themselves about the risks of developing a deep-vein thrombosis or a pulmonary embolism. The "education sessions" described in our prior 2004 and 2009 studies involved an audience of nurses, physicians and pharmacists only. Empowering patients with knowledge about the relative benefits and risks associated with VTE prophylaxis will allow them to make more informed decisions about their care once they are admitted.
In a "no blame" culture a key objective is risk reduction at the patient level and should likewise be fully ingrained in our everyday practice. Every clinician, including pharmacists, nurses and physicians must reach out to ensure that a common interest (VTE prophylaxis) is reached. This may take the form of raising questions about patients' VTE status at any given time during their hospital stay. This process during routine Kardex rounds may also serve as a great communication medium to bring awareness to other team members (dietitians, social workers, occupational therapists and physiotherapists), each of whom may serve to remind each other about patient VTE prophylaxis statuses. As a shared responsibility, these additional safeguards are required such that the "holes" do not line-up by way of the Swiss-Cheese Model and ultimately lead to patient harm.
As a follow-up to this quality improvement project, we are currently in the process of conducting a retrospective chart review to evaluate the safety and efficacy of optimal thromboprophylaxis prescribing habits. In this analysis, we plan to compare rates of symptomatic VTE events and bleeding prior to, and following enhanced rates of VTE prophylaxis. Our hypothesis is a decreasing trend of symptomatic VTE rates in tandem with an upward rise in VTE prophylaxis usage.
Our experience is reflective of the persistence that was essential to the longevity of this endeavor. We do, however, believe that the methodologies and results outlined in our study are reproducible and can be applied to other institutions, perhaps over a shorter timeframe. The effectiveness of the methodologies including defining of the current institutional baseline VTE prophylaxis rates at any given time, the use of the PDSA cycle to bring awareness to frontline staff of what was not done well, regroup, revamp and re-educate with new information, and promoting success stories of the team efforts at various levels of institution. Recognition of frontline staff and team with job-well-done completed the PDSA cycle. The maintenance phase reinforces the importance of our cause with the continuous audits and reporting of prophylaxis uptake rates over time. The positive results would also perpetuate the cycle. One of the critical components of completing a major task, especially in an institution as large as ours, is to involve all stakeholders at all levels. A multidisciplinary membership is a critical mass to this ongoing project. Further investigations and implementation of some of the described recommendations will ensure that assessment for VTE prophylaxis becomes a regular practice by clinicians in the future. The incremental increase in staff acceptance rate of this quality care measure is well-reflective of the value of cultural evolution.
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